• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在Shy-Drager综合征和帕金森病患者中,人类尾状核、黑质及额叶皮质中[3H]螺哌隆结合的改变。

Alterations in [3H]spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in the Shy-Drager syndrome and Parkinson's disease.

作者信息

Quik M, Spokes E G, Mackay A V, Bannister R

出版信息

J Neurol Sci. 1979 Nov;43(3):429-37. doi: 10.1016/0022-510x(79)90021-2.

DOI:10.1016/0022-510x(79)90021-2
PMID:521836
Abstract

[3H]Spiperone binding was investigated in the caudate nucleus, substantia nigra (s. nigra) and frontal cortex of control subjects and of patients with Parkinson's disease and the Shy-Drager syndrome. Binding sites for [3H]spiperone were interpreted as dopamine receptors in caudate and s. nigra, and as 5-hydroxytryptamine (5-HT) receptors in frontal cortex. Scatchard analysis showed that the Bmax (maximal number of binding sites) in caudate was similar in the 3 groups, whereas in s. nigra the Bmax was reduced by approximately 60% in both Parkinsons disease and Shy-Drager syndrome. The dissociation constant (Kd) for [3H]spiperone binding in s. nigra was similar in the 3 groups. In caudate nucleus, the Kd was similar in control and Parkinson groups; however, there was a significant increase in the dissociation constant in the caudate nucleus from cases of Shy-Drager syndrome. No differences in binding characteristics were observed in the frontal cortex. These results are taken to reflect a loss of dopamine receptor sites in the s. nigra in both Parkinson's disease and Shy-Drager syndrome, and a reduced affinity of dopamine receptor sites in the caudate nucleus in Shy-Drager syndrome.

摘要

在对照组、帕金森病患者和夏伊-德雷格综合征患者的尾状核、黑质和额叶皮质中研究了[3H]螺哌隆结合情况。[3H]螺哌隆的结合位点在尾状核和黑质中被解释为多巴胺受体,在额叶皮质中被解释为5-羟色胺(5-HT)受体。斯卡查德分析表明,尾状核中的Bmax(最大结合位点数)在三组中相似,而在黑质中,帕金森病和夏伊-德雷格综合征患者的Bmax均降低了约60%。三组中黑质中[3H]螺哌隆结合的解离常数(Kd)相似。在尾状核中,对照组和帕金森病组的Kd相似;然而,夏伊-德雷格综合征患者尾状核中的解离常数显著增加。在额叶皮质中未观察到结合特征的差异。这些结果被认为反映了帕金森病和夏伊-德雷格综合征患者黑质中多巴胺受体位点的丧失,以及夏伊-德雷格综合征患者尾状核中多巴胺受体位点亲和力的降低。

相似文献

1
Alterations in [3H]spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in the Shy-Drager syndrome and Parkinson's disease.在Shy-Drager综合征和帕金森病患者中,人类尾状核、黑质及额叶皮质中[3H]螺哌隆结合的改变。
J Neurol Sci. 1979 Nov;43(3):429-37. doi: 10.1016/0022-510x(79)90021-2.
2
[3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy.帕金森病和核上性麻痹中[3H]司哌罗宁结合、多巴胺及高香草酸浓度
Eur J Pharmacol. 1984 Mar 23;99(2-3):167-75. doi: 10.1016/0014-2999(84)90238-3.
3
Comparison of the binding of [3H]spiperone and [3H]domperidone in homogenates of mammalian retina and caudate nucleus.[3H]螺哌隆与[3H]多潘立酮在哺乳动物视网膜和尾状核匀浆中的结合比较。
J Neurochem. 1981 Nov;37(5):1130-43. doi: 10.1111/j.1471-4159.1981.tb04663.x.
4
[3H]Nitrendipine binding sites are decreased in the substantia nigra and striatum of the brain from patients with Parkinson's disease.
Brain Res. 1986 Jul 2;377(1):186-9. doi: 10.1016/0006-8993(86)91207-2.
5
Resolution of dopamine and serotonin receptor components of [3H]spiperone binding to rat brain regions.[3H]司哌罗宁与大鼠脑区结合的多巴胺和5-羟色胺受体成分的解析
Proc Natl Acad Sci U S A. 1981 Apr;78(4):2620-4. doi: 10.1073/pnas.78.4.2620.
6
[3H]spiperone binding in the nigrostriatal system in human brain.人脑黑质纹状体系统中[3H]螺哌隆结合情况
Eur J Pharmacol. 1984 Mar 23;99(2-3):159-65. doi: 10.1016/0014-2999(84)90237-1.
7
Dissociation between the presynaptic dopamine-sensitive adenylate cyclase and [3H]spiperone binding sites in rat substantia nigra.大鼠黑质中突触前多巴胺敏感性腺苷酸环化酶与[3H]螺哌隆结合位点之间的解离。
Brain Res. 1979 May 11;167(2):355-65. doi: 10.1016/0006-8993(79)90829-1.
8
Prenatal reserpine exposure in rats decreases caudate nucleus dopamine receptor binding in female offspring.大鼠孕期接触利血平会降低雌性后代尾状核多巴胺受体结合力。
Toxicol Lett. 1986 Jun;31(3):195-201. doi: 10.1016/0378-4274(86)90126-8.
9
Characterization of dopamine autoreceptor and [3H]spiperone binding sites in vitro with classical and novel dopamine receptor agonists.利用经典和新型多巴胺受体激动剂对多巴胺自身受体和[3H]螺哌隆结合位点进行体外表征。
Eur J Pharmacol. 1983 Mar 18;88(1):11-26. doi: 10.1016/0014-2999(83)90387-4.
10
Irreversible blockade of [3H]spiperone- but not [3H]dopamine-labeled dopamine receptors with phenoxybenzamine.用酚苄明对[³H]螺哌隆标记的多巴胺受体而非[³H]多巴胺标记的多巴胺受体进行不可逆阻断。
Biochem Pharmacol. 1981 Nov 15;30(22):3031-7. doi: 10.1016/0006-2952(81)90489-5.

引用本文的文献

1
mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.左旋多巴诱发异动症中的代谢型谷氨酸受体5、多巴胺D2受体和腺苷A2A受体
Curr Neuropharmacol. 2016;14(5):481-93. doi: 10.2174/1570159x14666151201185652.
2
Multiple system atrophy: pathophysiology and management.多系统萎缩:病理生理学与管理
CNS Drugs. 2001;15(11):839-52. doi: 10.2165/00023210-200115110-00003.
3
Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study.帕金森病和纹状体黑质变性中的多巴胺D1受体:一项正电子发射断层扫描研究。
J Neurol Neurosurg Psychiatry. 1993 May;56(5):467-72. doi: 10.1136/jnnp.56.5.467.
4
Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT.多系统萎缩:自然病史、MRI形态学以及用123I-BZM单光子发射计算机断层扫描进行多巴胺受体成像
J Neurol Neurosurg Psychiatry. 1994 Sep;57(9):1047-56. doi: 10.1136/jnnp.57.9.1047.
5
Predictors for improvement after electroconvulsive therapy in parkinsonian patients with on-off symptoms.帕金森病开关现象患者接受电休克治疗后症状改善的预测因素
J Neural Transm. 1981;52(3):199-211. doi: 10.1007/BF01249604.
6
The use of lisuride in the treatment of multiple system atrophy with autonomic failure (Shy-Drager syndrome).利苏瑞肽在治疗伴有自主神经功能衰竭的多系统萎缩(夏伊-德雷格综合征)中的应用。
J Neurol Neurosurg Psychiatry. 1981 Apr;44(4):347-51. doi: 10.1136/jnnp.44.4.347.
7
L-dopa reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatum.左旋多巴可逆转帕金森病纹状体中多巴胺D2受体密度的升高。
J Neural Transm. 1985;64(2):93-103. doi: 10.1007/BF01245971.
8
Pharmacological implications for neuroreceptor imaging.
Eur J Nucl Med. 1991;18(7):482-502. doi: 10.1007/BF00181287.